Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06385509 · ClinicalTrials.gov registry record · Phase 4
A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months
A Phase 4 study of Hypogonadism, sponsored by Tolmar.
- Active
- Registry status
- Phase 4
- Development phase
- 110
- Enrollment target
- 20
- Study locations
NCT06385509 is a Phase 4 study of Hypogonadism that is active but no longer recruiting, run by Tolmar. The registered enrollment target is 110 participants, roughly in line with the 115-participant average among 21 other Hypogonadism trials with a reported enrollment target. The trial reports 20 study locations across 9 states.
The verdict
NCT06385509, a Phase 4 study of Hypogonadism, is active but no longer recruiting, sponsored by Tolmar.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 110 participants
- Enrollment target
- 20
- Study locations
Study Summary
TOL-CLAR-20024 is a Phase 4, multi-center, open-label safety study evaluating the potential effect of JATENZO on adrenal function in hypogonadal men treated with JATENZO for 12 months.
Conditions Studied
Interventions
- DRUG Jatenzo
Study Locations (20)
Florida
- Hillcrest Medical Research, LLC - DeLand
- Global Health Clinical Trial Crop - Miami
- Reserka LLC - Miami
- Renstar Medical Research - Ocala
- Clinical Research Center of Florida - Pompano Beach
North Carolina
- Velocity Clinical Research, Inc. - Durham
- Catawba Valley Medical Group, Inc. - Hickory
- Raleigh Medical Group - Raleigh
- Piedmont Healthcare, PA - Statesville
- Wilmington Health, PLLC - Wilmington
California
- Clinical Trials Research - Lincoln
- Long Beach Research Institute, LLC - Long Beach
- Integrated Clinical Research - Tarzana
New York
- AccuMed Research Associates - Garden City
- Rochester Clinical Research, LLC - Rochester
Arizona
- Alliance for Multispecialty Research - Tempe
Georgia
- Velocity Clinical Research - Savannah
Maryland
- Centennial Medical Group - Columbia
Nebraska
- Velocity Clinical Research - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2024-05-10 |
| Est. Completion | 2026-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06385509
The ClinicalTrials.gov registry entry for NCT06385509 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 115-participant average among 21 other Hypogonadism trials with a reported enrollment target. The listed sponsor is Tolmar, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypogonadism appearing as the primary indexed condition, and to 1 intervention - of which Jatenzo is the first listed.
NCT06385509 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, North Carolina, California.
Frequently Asked Questions
What is clinical trial NCT06385509 about?
NCT06385509 is a clinical study titled "A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months". TOL-CLAR-20024 is a Phase 4, multi-center, open-label safety study evaluating the potential effect of JATENZO on adrenal function in hypogonadal men treated with JATENZO for 12 months.
What is the current status of trial NCT06385509?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 110 participants. The study started on 2024-05-10. Estimated completion is 2026-03.
What conditions does trial NCT06385509 study?
This clinical trial studies the following conditions: Hypogonadism.
What interventions are being tested in trial NCT06385509?
The interventions under investigation include: Jatenzo (DRUG).
Who is sponsoring clinical trial NCT06385509?
This trial is sponsored by Tolmar, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06385509 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypogonadism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adaptions and Resiliency to Multi-Stressor OpeRations
RECRUITING · Phase 4
-
Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism
ACTIVE NOT RECRUITING · Phase 4
-
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
COMPLETED · Phase 4
-
Testosterone Replacement in Older Men and Atherosclerosis Progression
COMPLETED · Phase 4
-
Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement
COMPLETED · Phase 4
-
Observation of Environment and Reproductive-Endocrine Effects
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.